Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine

Variability in response to antiplatelet therapy can be explained in part by pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of-function and gain-of-function variants help explain these interindividual differences. Individuals may carry multiple variants, with linkage disequilibrium noted among some alleles. In the current pharmacogenomics era, genomic variation in CYP2C19 has led to the definition of pharmacokinetic phenotypes for response to antiplatelet therapy, in particular, clopidogrel. Individuals may be classified as poor, intermediate, extensive, or ultrarapid metabolizers, based on whether they carry wild type or polymorphic CYP2C19 alleles. Variant alleles differentially impact platelet reactivity, concentration of plasma clopidogrel metabolites, and clinical outcomes. Interestingly, response to clopidogrel appears to be modulated by additional factors, such as sociodemographic characteristics, risk factors for ischemic heart disease, and drug-drug interactions. Furthermore, systems medicine studies suggest that a broader approach may be required to adequately assess, predict, preempt, and manage variation in antiplatelet response. Transcriptomics, epigenomics, exposomics, miRNAomics, proteomics, metabolomics, microbiomics, and mathematical, computational, and molecular modeling should be integrated with pharmacogenomics for enhanced prediction and individualized care. In this review of pharmacogenomic variation of CYP450, a systems medicine approach is described for tailoring antiplatelet therapy in clinical practice of precision cardiovascular medicine.

• Publication year

  2018

• Venue

  Journal of Personalized Medicine

• Publication date

  2018-01-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/jpm8010008PMID 29385765PMCID 5872082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clopidogrel pharmacogenetics: Beyond candidate genes and genome‐wide association studies

  2017influential reference
• The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems

  2017cited by this paper
• Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing Projects

  2017cited by this paper
• Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance

  2017cited by this paper
• Gut Microbe-Generated Trimethylamine N-Oxide From Dietary Choline Is Prothrombotic in Subjects.

  2017cited by this paper
• The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics

  2017influential reference
• Intestinal Microbiota‐Generated Metabolite Trimethylamine‐N‐Oxide and 5‐Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intestinal Microbiota in a COURAGE‐Like Patient Cohort

  2016cited by this paper
• The influence of non-steroidal anti-inflammatory drugs on the gut microbiome.

  2016cited by this paper
• Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk.

  2016cited by this paper
• The impact of P2Y12 promoter DNA methylation on the recurrence of ischemic events in Chinese patients with ischemic cerebrovascular disease

  2016cited by this paper
• Interindividual Variability in Cytochrome P450–Mediated Drug Metabolism

  2016influential reference
• Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.

  2016cited by this paper
• Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.

  2016cited by this paper
• Trimethylamine N-Oxide: The Good, the Bad and the Unknown

  2016cited by this paper
• Pharmacogenetics of Clopidogrel: An Unresolved Issue

  2016influential reference
• Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics

  2015cited by this paper
• Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment

  2015influential reference
• Inflammatory and Antioxidant Pattern Unbalance in “Clopidogrel-Resistant” Patients during Acute Coronary Syndrome

  2015cited by this paper
• Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.

  2015influential reference
• Future Translational Applications From the Contemporary Genomics Era: A Scientific Statement From the American Heart Association

  2015cited by this paper
• Clinical Implementation of Cardiovascular Pharmacogenomics.

  2015cited by this paper
• The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles

  2015influential reference
• Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome

  2015influential reference
• Systems biology approaches to adverse drug effects: the example of cardio-oncology

  2015influential reference
• Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions

  2015cited by this paper
• Genotype-based clinical trials in cardiovascular disease

  2015cited by this paper
• Changes of High Sensitivity C-Reactive Protein During Clopidogrel Therapy in Patients Undergoing Percutaneous Coronary Intervention

  2015cited by this paper
• Intraprocedural thrombotic event during coronary intervention depends on CYP2C19 genotype and is a predictor of future clinical event.

  2015cited by this paper
• Analysis of DNA methylation landscape reveals the roles of DNA methylation in the regulation of drug metabolizing enzymes

  2015cited by this paper
• 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention

  2014influential reference
• Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.

  2014influential reference
• P2Y12 Antagonists: Pharmacology, Efficacy and Patient Considerations

  2014cited by this paper
• Analysis of compound heterozygous CYP2C19 genotypes to determine cis and trans configurations.

  2014cited by this paper
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel

  2014cited by this paper
• Association of P2Y12 Gene Promoter DNA Methylation with the Risk of Clopidogrel Resistance in Coronary Artery Disease Patients

  2014cited by this paper
• Pharmacogenetic landscape of clopidogrel in north Indians suggest distinct interpopulation differences in allele frequencies.

  2014cited by this paper
• Different Influences of Hematocrit on the Results of Two Point-Of-Care Platelet Function Tests, the VerifyNow Assay and Multiple Electrode Platelet Aggregometry

  2014cited by this paper
• Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial.

  2014cited by this paper
• Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response.

  2013cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

  2013influential reference
• The CYP2C19*17 variant is not independently associated with clopidogrel response

  2013cited by this paper
• Regulatory polymorphisms in CYP2C19 affecting hepatic expression

  2013influential reference
• Faculty Opinions recommendation of 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• African variation at Cytochrome P450 genes

  2013cited by this paper
• The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease.

  2013cited by this paper
• Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.

  2013cited by this paper
• Platelet function and genetic testing.

  2013cited by this paper
• CYP2C19 Poor Metabolizer Is Associated With Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction But Not Stable Angina

  2013cited by this paper
• Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention.

  2013influential reference
• Evolutionary aspects and the implications for the treatment of infectious diseases

  2013cited by this paper
• The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response

  2013cited by this paper
• Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.

  2013cited by this paper
• Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness

  2013cited by this paper
• CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease

  2013cited by this paper
• P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?

  2013cited by this paper
• Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy.

  2013cited by this paper
• Transcriptional regulation of CYP2C19 and its role in altered enzyme activity.

  2012cited by this paper
• ABCB1 C3435T Polymorphism and Response to Clopidogrel Treatment in Coronary Artery Disease (CAD) Patients: A Meta-Analysis

  2012cited by this paper
• Personalized medicine.

  2012cited by this paper
• The Metabolomic Paradigm of Pharmacogenomics in Complex Disorders

  2012influential reference
• Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.

  2012cited by this paper
• Genomics and pharmacogenomics of brain disorders.

  2012cited by this paper
• Clopidogrel and Genetic Testing: Is It Necessary for Everyone?

  2012cited by this paper
• Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics

  2012cited by this paper
• The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.

  2012cited by this paper
• Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.

  2012cited by this paper
• Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19

  2012cited by this paper
• Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.

  2012cited by this paper
• Human CYP2C8 Is Post-Transcriptionally Regulated by MicroRNAs 103 and 107 in Human Liver

  2012cited by this paper
• Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.

  2012cited by this paper
• Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: importance of metabolites.

  2012cited by this paper
• Association of estimated GFR with platelet inhibition in patients treated with clopidogrel.

  2012cited by this paper
• Bedside monitoring to adjust antiplatelet therapy for coronary stenting.

  2012cited by this paper
• Metabotype Concept: Flexibility, Usefulness and Meaning in Different Biological Populations

  2012cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy

  2011cited by this paper
• How to minimize stent thrombosis.

  2011cited by this paper
• ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

  2011cited by this paper
• Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

  2011cited by this paper
• Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.

  2011cited by this paper
• Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes

  2011cited by this paper
• Pharmacogenomics of clopidogrel: evidence and perspectives.

  2011cited by this paper
• CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.

  2011cited by this paper
• ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

  2011cited by this paper
• High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial

  2011cited by this paper
• Effect of CYP2C19*2 and *3 Loss-of-Function Alleles on Platelet Reactivity and Adverse Clinical Events in East Asian Acute Myocardial Infarction Survivors Treated With Clopidogrel and Aspirin

  2011cited by this paper
• The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.

  2011cited by this paper
• Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness

  2011cited by this paper
• In silico identification of microRNAs predicted to regulate the drug metabolizing cytochrome P450 genes.

  2011cited by this paper
• Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-.

  2011cited by this paper
• Clopidogrel-drug interactions.

  2011cited by this paper
• Personalized medicine: new genomics, old lessons

  2011cited by this paper
• Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

  2011influential reference
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cited by this paper
• Functional Genomics Applied to Cardiovascular Medicine

  2011influential reference
• Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

  2010influential reference
• MicroRNAs add a new dimension to cardiovascular disease.

  2010cited by this paper

• Antiplatelet dilemma: Clopidogrel or aspirin for long-term cardiovascular protection after dual antiplatelet therapy following PCI.

  2026cites this paper
• Drug-gene interactions and the risk of diabetic microvascular complications: A population-based cohort study.

  2026cites this paper
• Therapeutic Potential and Predictive Pharmaceutical Modeling of Indole Kratom Alkaloids

  2025cites this paper
• CYP450 activity, drug interactions and genetic polymorphisms: clinical relevance for the new selective cardiac myosin inhibitors.

  2025cites this paper
• Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis

  2025cites this paper
• From sample to clinical insight: a review of exome sequencing in disease diagnostics.

  2025cites this paper
• The impact of the exposome on cytochrome P450-mediated drug metabolism

  2025cites this paper
• Diabetic Platelets: Pathophysiology, Clinical Significance, and Therapeutic Perspectives

  2025cites this paper
• THE ROLE OF ΑIIBΒ3 RECEPTORS IN MYOCARDIAL INFARCTION: MECHANISMS AND THERAPEUTIC STRATEGIES

  2025cites this paper
• Pharmacogenomics Applications in Clinical Practice: Revolutionizing Patient Care

  2025cites this paper
• Hepatic Cytochrome P450 Enzymatic System Interaction With Platelet Function and Cardiovascular Outcomes—Pharmacogenomic Impact on Inter‐Organ Communication

  2025influential citation
• The role of genomics and proteomics in drug discovery and its application in pharmacy

  2025cites this paper
• Pretreatment With P2Y12 Inhibitors in Contemporary Practice: Where Do We Stand?

  2025cites this paper
• The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease

  2025cites this paper
• CYP2C19 and CES1 gene variants affecting clopidogrel metabolism in a South Asian population from Sri Lanka.

  2025cites this paper
• Evaluation of response to clopidogrel in patients with CYP2C19*2/*3 polymorphisms and its association with miR-19b expression

  2025cites this paper
• Evolution of Cardiovascular Science: From Anatomy to Multiomics

  2025cites this paper
• Effect of cytochrome P450 2C19 (CYP2C19) gene polymorphism and clopidogrel reactivity on long term prognosis of patients with coronary heart disease after PCI.

  2024cites this paper
• Biochemical Mechanisms in Drug Metabolism: Implications for Personalized Pharmacotherapy in Pharmacy Practice

  2024cites this paper
• Exploring the preparedness of hospital pharmacists practising in Southwest London for implementing pharmacogenomics testing

  2024cites this paper
• Cost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients

  2024cites this paper
• Subacute in-stent thrombosis after carotid artery stenting in a patient with gene polymorphisms associated with aspirin and clopidogrel resistance: a case report

  2024cites this paper
• A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients

  2024cites this paper
• Clopidogrel resistance and its effect on clinical outcomes in acute coronary syndrome

  2024cites this paper
• The Diversity of CYP2C19 Polymorphisms in the Thai Population: Implications for Precision Medicine

  2024cites this paper
• Genetic Polymorphisms in CYP2 Gene Family in Bulgarian Individuals and their Clinical Implications

  2024cites this paper
• The diversity and clinical implications of genetic variants influencing clopidogrel bioactivation and response in the Emirati population

  2024cites this paper
• Pharmacoeconomic analysis of personalized antiplatelet therapy in patients with acute coronary syndromer

  2023cites this paper
• Advances and Perspectives in methods for identifying high platelet reactivity

  2023cites this paper
• Are Community Pharmacists Ready to Deliver Pharmacogenomics Testing Services?

  2023cites this paper
• Thromboelastographic and Gene Polymorphism Bimodality Detection for Dual Antiplatelet Aggregation Therapy in Individuals with Clopidogrel-resistant Symptomatic Intracranial Artery Stenosis

  2023cites this paper
• Advancing stroke genetics in Hawai‘i and the Pacific Islands

  2023cites this paper
• Trends in Dual Antiplatelet Therapy Use for Neurointerventional Procedures for the Management of Intracranial Aneurysms

  2023cites this paper
• Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study

  2023influential citation
• COST-UTILITY ANALYSIS OF PERSONALIZED ANTIPLATELET THERAPY

  2023cites this paper
• The Signaling Pathway of the ADP Receptor P2Y12 in the Immune System: Recent Discoveries and New Challenges

  2023influential citation
• Research Progress on Related Genes of Clopidogrel Resistance

  2023cites this paper
• Signatures of Co-evolution and Co-regulation in the CYP3A and CYP4F Genes in Humans

  2023cites this paper
• Green tea polyphenols in cardiometabolic health: A critical appraisal on Phytogenomics towards personalized green tea

  2022cites this paper
• Prevalence of CYP2C19 681G>A and 636G>A Gene Polymorphisms in Javanese Farmers Exposed to Chlorpyrifos

  2022cites this paper
• Prevention of Anthracycline-Induced Cardiotoxicity: The Good and Bad of Current and Alternative Therapies

  2022cites this paper
• Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status

  2022cites this paper
• Pharmacogenetics of Antiplatelet Therapy.

  2022cites this paper
• Sex Differences in Clopidogrel Effects Among Young Patients With Acute Coronary Syndrome: A Role for Genetics?

  2022cites this paper
• Genetic Polymorphism of CYP2C19 in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (PCI) in Erbil

  2022cites this paper
• Detection of The Effect of CYP2C19*4 Mutation on Clopidogrel Response by In Silico Methods

  2022cites this paper
• Pharmacogenetics of CYP2C19*17: Functional and Clinical Implications of CYP2C19*17 - rs12248560 (c.-806C>T) in the Development of Type 2 Diabetes

  2022cites this paper
• Bleeding associated with co-administration of clopidogrel and ACEi in patients undergoing PCI and DAPT.

  2021cites this paper
• Cytochrome P450 Enzymes and Drug Metabolism in Humans

  2021cites this paper
• Classification of drugs for evaluating drug interaction in drug development and clinical management.

  2021cites this paper
• E cacy and Safety of Low-Dose Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome or Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis

  2021cites this paper
• The effect of loss-of-function allele (CYP2C19*3) with Clopidogrel efficacy in coronary heart disease patients

  2021cites this paper
• Prevalence of CYP2C19 and ITGB3 polymorphisms among Bangladeshi patients who underwent percutaneous coronary intervention

  2021cites this paper
• A Clinical Update on Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke

  2021cites this paper
• PGPM_A_224894 569..577

  2021cites this paper
• Clinical importance of testing for clopidogrel resistance in patients undergoing carotid artery stenting—a systematic review

  2021cites this paper
• An Analysis of Pharmacogenomic-Guided Pathways and Their Effect on Medication Changes and Hospital Admissions: A Systematic Review and Meta-Analysis

  2021cites this paper
• Short- and long-term cost-effectiveness of CYP2C19 genotype-guided therapy, universal clopidogrel, and universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.

  2021cites this paper
• POLIMORFISME CYP2C19*2 TERHADAP AGREGASI PLATELET DAN KEJADIAN KARDIOVASKULAR PADA PASIEN PENYAKIT JANTUNG KORONER

  2021cites this paper
• Human Variability in Carboxylesterases and carboxylesterase-related Uncertainty Factors for Chemical Risk Assessment.

  2021cites this paper
• Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis.

  2021cites this paper
• Interactions between cardiology and oncology drugs in precision cardio-oncology.

  2021cites this paper
• A Pharmacogenetic Study of CYP2C19 in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy

  2021influential citation
• Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example

  2021cites this paper
• Flavonoids as potential anti-platelet aggregation agents: from biochemistry to health promoting abilities

  2021cites this paper
• The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)

  2021cites this paper
• The Role of Current Major Antiplatelet Agents in Cardiovascular Diseases

  2020cites this paper
• Impact of Reduced-Dose Prasugrel vs. Standard-Dose Clopidogrel on In-Hospital Outcomes of Percutaneous Coronary Intervention in 62,737 Patients with Acute Coronary Syndromes: A Nationwide Registry Study in Japan.

  2020cites this paper
• Major CYP450 polymorphism Among Saudi Patients.

  2020cites this paper
• Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics

  2020cites this paper
• Individualized Medication Management in Ontario Long-Term Care Clinical Impact on Management of Depression, Pain, and Dementia.

  2020cites this paper
• Whole Genome Sequencing Identifies Novel Functional Loci Associated with Lung Function in Puerto Rican Youth.

  2020cites this paper
• Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR

  2020cites this paper
• The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology

  2020influential citation
• New paradigm for expediting drug development in Asia.

  2020cites this paper
• Pharmacogenomics in Clinical Care: Implications for Public Health

  2020cites this paper
• Genomics Testing and Personalized Medicine in the Preoperative Setting.

  2020cites this paper
• The Impact of Kinase Insert Domain (KDR) Gene Polymorphism rs2305948 on Clopidogrel Resistance in Iraqi Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)

  2020cites this paper
• Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention

  2020cites this paper
• Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.

  2020cites this paper
• Prevalence and types of genetic polymorphisms of CYP2C19 and their effects on platelet aggregation inhibition by clopidogrel.

  2020cites this paper
• Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder

  2020cites this paper
• F2R Polymorphisms and Clopidogrel Efficacy and Safety

  2020cites this paper
• Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C9*3 and CYP2C19*3 Gene Variations With Type 2 Diabetes: A Case-Control Study.

  2020cites this paper
• Genetic Polymorphisms and Perioperative Bleeding in Off-pump Coronary Artery Bypass Grafting Surgery.

  2020cites this paper
• Human Cell Modeling for Cardiovascular Diseases

  2020cites this paper
• Indication

  2019cites this paper
• Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing PCI: a randomized controlled clinical trial.

  2019cites this paper
• Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention

  2019cites this paper
• Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study

  2019cites this paper
• CYP 2 C 19 Genetic Polymorphism in the East of Iran : It ' s Association with the Severity and Pattern of Coronary Artery Disease

  2019cites this paper
• Clopidogrel‐associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients

  2018cites this paper
• Preface to Special Issue on ‘Cytochrome P450 Variation in Pharmacogenomics’

  2018cites this paper
• Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.

  2018cites this paper
• Genomics Testing and Personalized Medicine in the Preoperative Setting.

  2018cites this paper
• Introduction to Clinical Pharmacology

  year unknowncites this paper